Remarkably, the IgG3 point mutant IgG3-E430G performed significantly more efficiently than the respective parental IgG3 on these tumor cell lines, a difference that was not observed when targeted against bacterial polysaccharides (23). The gene discussed is IGHG3; the disease is neoplasm.